Christopher Anzalone

Chairman, Chief Executive Officer & President, Arrowhead Pharmaceutical

Search every verified Christopher Anzalone interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Christopher Anzalone, president, CEO, and director of Arrowhead Pharmaceuticals, has continued to advance the company's RNA interference (RNAi) platform, with a focus on expanding delivery beyond the liver into new cell types such as solid tumors, lung, and skeletal muscle. In 2023, he stated that the company expects to announce the next cell type it will target in the first half of the yearikuha. Anzalone has described RNAi as "the best bet in biotech," citing its surgical precision and durability, with some drugs showing activity for more than six months from a single injection. He has also emphasized the company's strategy of focusing on genetically validated targets to de-risk clinical programs. On the financial and partnership front, Anzalone noted that Arrowhead sold potential royalties from its Amgen-partnered cardiovascular drug olpasiran to Royalty Pharma for $250 million upfront, with up to $160 million in additional payments, while retaining rights to $400 million in milestone payments from Amgen. He has highlighted the company's "20 and 25" program, aiming to have 20 drug candidates in clinical trials or on the market by 2025. Anzalone has also discussed plans to commercialize certain drugs internally, including a cardiovascular outcome study for its wholly owned candidate ARO-ANG3, which he said has shown "unequivocal" data. He has characterized the current period as "the first inning of the RNA interference game," predicting that dozens of powerful medicines will reach patients in the coming years.